Emergent Biosolutions (EBS) Tops Q1 EPS by 13c; Guides Q2 Sales
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $5.08 +5.39%
Financial Fact:
Other income (expense), net: -234K
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Other income (expense), net: -234K
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Emergent Biosolutions (NYSE: EBS) reported Q1 EPS of ($0.02), $0.13 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $50.3 million versus the consensus estimate of $47.32 million.
Sees Q2 2012 revenue of $70-$80 million, versus the consensus of $76.6 million.
For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.
Sees Q2 2012 revenue of $70-$80 million, versus the consensus of $76.6 million.
For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- CoStar Group acquires Zonda for $800M, adding new home data
- Faraday Future signs robotics distributor deal, plans partner event
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
